Advertisement
UK markets closed
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     
  • AIM

    789.87
    +6.17 (+0.79%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     
  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     
  • Bitcoin GBP

    48,516.76
    -1,679.69 (-3.35%)
     
  • CMC Crypto 200

    1,260.43
    -97.58 (-7.19%)
     
  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     
  • DOW

    39,512.84
    +125.08 (+0.32%)
     
  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     
  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,772.85
    +86.25 (+0.46%)
     
  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     

The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5%

during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

New York, April 29, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Immuno Oncology Assays Market by Product & Service, Technology, Cancer Indications, Application - Global Forecast to 2026" - https://www.reportlinker.com/p05744470/?utm_source=GNW
On the other hand,the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.

The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period
The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service.In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market.

The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.

Research applications segment accounted for the highest CAGR
Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics.In 2020, the research applications segmentaccounted for the highest growth rate.

This can be attributed to the rising prominence of biomarker-based drug development.

Asia Pacific: The fastest-growing regionimmuno-oncology assays market
The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.The Asia Pacific region is projected to register the highest CAGR during the forecast period.

Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Agilent Technologies, Inc. (US)
• Illumina, Inc. (US)
• NanoString Technologies, Inc. (US)
• Sartorius AG (Germany)
• HTG Molecular Diagnostics, Inc. (US)
• QIAGEN N.V. (Netherlands)
• Merck Millipore (US)
• PerkinElmer, Inc. (US)
• Abbott Laboratories, Inc. (US)
• Guardant Health, Inc. (US)
• bioMérieux SA (France)
• Myriad Genetics, Inc. (US)
• MESO SCALE DIAGNOSTICS, LLC. (US)
• Seegene Inc. (South Korea)
• Bio-Rad Laboratories, Inc. (US)
• Charles River Laboratories, Inc. (US)
• Olink (Sweden)
• ASURAGEN, INC. (US)
• Invivoscribe, Inc. (US)
• Creative Biolabs (US)
• ReachBio LLC (US)
• NMI Technologietransfer GmbH (Germany)

Research Coverage:
This report provides a detailed picture of the global immuno-oncology assays market.It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Read the full report: https://www.reportlinker.com/p05744470/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001